Global Prions Testing Industry Outlook: Immunoassay-RT-QuIC-Sequencing Technologies, Clinical Neurology-Laboratory Diagnosis Applications, and Zoonotic Disease Monitoring 2026-2032

Introduction: Addressing Zoonotic Transmission Risk, Preclinical Diagnosis Gaps, and Blood Supply Safety Pain Points

For public health agencies, blood safety regulators, and livestock disease control authorities, prion diseases—transmissible spongiform encephalopathies (TSEs)—present unique diagnostic challenges. Unlike bacterial or viral pathogens, prions (misfolded PrP^Sc proteins) contain no nucleic acids (DNA/RNA), cannot be amplified by PCR, and have long incubation periods (years to decades) before clinical symptoms appear. Classic Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle (“mad cow disease”), scrapie in sheep, and chronic wasting disease (CWD) in deer/elk are invariably fatal, with no cure or treatment. Variant CJD (vCJD) from BSE-contaminated beef products (1990s UK outbreak) demonstrated zoonotic transmission, raising concerns about blood transfusion transmission (vCJD cases linked to blood products) and iatrogenic transmission (contaminated surgical instruments, corneal grafts, human growth hormone). Post-mortem diagnosis (brain biopsy, autopsy) is the gold standard, but antemortem testing (blood, CSF, urine, tonsil biopsy) has low sensitivity, long turnaround times (weeks), and limited availability. Prion testing methods—immunoassays (ELISA, Western blot), molecular biology (RT-QuIC, PMCA), and histopathology—are critical for: clinical neurology diagnosis (suspected CJD cases), laboratory diagnosis (blood donor screening, tissue safety), research (drug discovery, pathogenesis), and veterinary surveillance (BSE, scrapie, CWD). As CWD spreads across North America (30+ US states, 3 Canadian provinces, Nordic countries), as blood safety regulations tighten (FDA guidance on vCJD deferral), and as research accelerates (prion-like mechanisms in Alzheimer’s, Parkinson’s), demand for prion testing is growing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Prions Testings – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Prions Testings market, including market size, share, demand, industry development status, and forecasts for the next few years.

For infectious disease epidemiologists, blood safety officers, and veterinary diagnostic laboratory directors, the core pain points include achieving high sensitivity for low prion concentrations (10⁻¹² g/mL in blood), reducing turnaround time (days to hours for RT-QuIC vs. weeks for animal bioassay), and ensuring test specificity (distinguish PrP^Sc from normal PrP^C). According to QYResearch, the global prions testing market was valued at US$ 1,712 million in 2025 and is projected to reach US$ 2,531 million by 2032, growing at a CAGR of 5.8% .

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097680/prions-testings

Market Definition and Core Capabilities

Prions testing refers to laboratory methods and diagnostic assays to detect presence, activity, or misfolding of prion proteins (PrP^Sc), the infectious agents responsible for transmissible spongiform encephalopathies (TSEs). Core capabilities:

• Immunoassays (40–45% of revenue, largest segment): ELISA (enzyme-linked immunosorbent assay) – detects PrP^Sc in brain tissue (BSE, scrapie, CWD surveillance) using monoclonal antibodies (e.g., 6H4, 12F10). Western blot (immunoblot) – confirmatory test (differentiates glycosylation patterns). Lateral flow immunoassays (rapid tests) – for field use (slaughterhouse BSE screening, CWD testing in hunter-harvested deer). Sensitivity: 1–10 ng/mL (brain homogenate). High throughput (96/384-well plates). Used for livestock surveillance (BSE, scrapie, CWD) and post-mortem human diagnosis (CJD).
• Molecular Biology Techniques (30–35% of revenue, fastest-growing at 6–7% CAGR): RT-QuIC (real-time quaking-induced conversion) – ultrasensitive detection of PrP^Sc in cerebrospinal fluid (CSF), blood, urine, nasal brushings, and olfactory mucosa. Amplifies misfolded prions using recombinant PrP substrate and thioflavin T (fluorescence). Sensitivity: femtogram (10⁻¹⁵ g/mL) level. Turnaround: 12–72 hours. Used for antemortem CJD diagnosis (CSF RT-QuIC sensitivity 80–90%, specificity 99–100%). PMCA (protein misfolding cyclic amplification) – similar to RT-QuIC, but uses sonication. High sensitivity but lower throughput.
• Others (20–25% of revenue): Histopathology (vacuolation, spongiform change, PrP immunohistochemistry) – gold standard post-mortem. Animal bioassay (mouse inoculation) – research only (months to years). Mass spectrometry (detection of PrP peptides) – emerging research tool. Next-generation sequencing (prion gene PRNP mutations) – for genetic CJD (familial TSE).

Market Segmentation by Application

• Clinical Neurology (35–40% of revenue, largest segment): Sporadic CJD (sCJD, 85% of cases), familial CJD (fCJD, 10–15%, PRNP mutations), iatrogenic CJD (iCJD, <1%, contaminated medical equipment), and variant CJD (vCJD, linked to BSE exposure, declining since 2000). RT-QuIC on CSF is first-line antemortem test (sensitivity 80–90%, specificity >99%). MRI (basal ganglia hyperintensity), EEG (periodic sharp wave complexes), and 14-3-3 protein (CSF) support diagnosis. National CJD surveillance programs (UK, US, EU, Japan, Australia) drive testing volume.
• Laboratory Diagnosis (30–35% of revenue, fastest-growing at 6–7% CAGR): Blood donor screening (vCJD risk – deferral policies in UK, France, Ireland, deferral of donors with prolonged UK residence). Tissue safety screening (corneal grafts, dura mater grafts, human growth hormone). Surgical instrument sterilization validation (PrP^Sc resists standard autoclaving, requires NaOH or enzymatic cleaning). Laboratory-acquired infection prevention (BSL-2/BSL-3 precautions for brain tissue). Emerging blood-based RT-QuIC (research use only, not yet approved for donor screening).
• Research and Translational Research (20–25% of revenue): Drug discovery (prion propagation inhibitors, anti-PrP antibodies, small molecules targeting misfolding). Pathogenesis studies (PrP^Sc conversion mechanisms, strain diversity). Prion-like mechanisms in neurodegenerative diseases (Alzheimer’s Aβ, Parkinson’s α-synuclein, Huntington’s huntingtin, ALS TDP-43). Prion detection method development (single-molecule detection, biosensors, nanoscale imaging).
• Others (5–10% of revenue): Veterinary surveillance (BSE: EU mandatory testing of cattle >48 months, Japan, Canada, US; scrapie: EU, US scrapie eradication program; CWD: North America, Scandinavia, South Korea – mandatory testing in captive deer/elk, hunter-harvested surveillance). Food safety testing (specified risk material removal – brain, spinal cord from cattle >30 months). Zoonotic risk monitoring (CWD transmission to humans? limited evidence, but WHO/FDA/CDC monitoring).

Technical Challenges and Industry Innovation

The industry faces four critical hurdles. Low prion concentration in peripheral tissues (blood, urine, CSF) for early-stage or pre-symptomatic CJD, vCJD, CWD requires ultrasensitive methods (RT-QuIC, PMCA) with amplification steps (2–10 days, risk of contamination). Specificity challenges distinguishing PrP^Sc from normal PrP^C (same amino acid sequence, different conformation). Monoclonal antibodies (6H4, 12F10) detect epitopes exposed only in misfolded form; RT-QuIC uses recombinant PrP substrate (no cross-reactivity). Standardization and reference materials for inter-laboratory comparability (WHO International Standard for CJD, CWD, BSE). WHO reference reagents for RT-QuIC (lyophilized brain homogenate, recombinant PrP) distributed to national reference labs. Regulatory approval pathways for antemortem tests (FDA, EMA, PMDA). RT-QuIC for CJD diagnosis is laboratory-developed test (LDT) in US (CLIA-certified labs), not FDA-approved. In Europe, RT-QuIC is used under CE-IVD (in vitro diagnostic) for CSF testing. Blood-based RT-QuIC not yet approved for donor screening (FDA requires clinical validation studies).

独家观察: CWD Spread Driving Veterinary Surveillance and Public Health Concern

An original observation from this analysis is the double-digit growth (8–9% CAGR) of CWD (chronic wasting disease) testing in North America and Scandinavia, outpacing human CJD diagnosis (4–5% CAGR). CWD prevalence in captive and free-ranging deer/elk populations exceeds 10–30% in endemic areas (Colorado, Wyoming, Wisconsin, Saskatchewan, Norway, Finland, South Korea). CWD spreads via direct contact, contaminated environment (prions persist in soil for years), and carcass disposal. Transmission to humans? No confirmed cases (unlike BSE/vCJD), but in vitro studies show limited conversion of human PrP^C to PrP^Sc by CWD prions. WHO, FDA, CDC recommend caution (avoid consumption of CWD-positive meat). CWD testing mandatory for captive deer/elk herds (USDA APHIS CWD Herd Certification Program) and voluntary for hunter-harvested surveillance. CWD RT-QuIC on lymph node, recto-anal mucosa associated lymphoid tissue (RAMALT), or obex (brainstem) with sensitivity >95%. CWD testing market projected 30%+ of veterinary prion testing revenue by 2028 (vs. 20% in 2025).

Strategic Outlook for Industry Stakeholders

For CEOs, public health laboratory directors, and veterinary diagnostic investors, the prions testing market represents a steady-growth (5.8% CAGR), niche-diagnostic opportunity anchored by CWD spread, blood safety regulations, and RT-QuIC adoption for antemortem CJD diagnosis. Key strategies include:

• Investment in RT-QuIC platforms (automated, high-throughput) for CWD surveillance, CJD diagnosis, and blood safety research.
• Development of blood-based RT-QuIC (plasma, serum, buffy coat) for pre-symptomatic CJD and vCJD donor screening (FDA guidance, clinical validation).
• Expansion into CWD testing (North America, Scandinavia, South Korea) with rapid (hours), field-deployable lateral flow immunoassays and laboratory-based RT-QuIC.
• Geographic expansion into North America (CWD surveillance), Europe (CJD surveillance, blood safety), and Asia-Pacific (Japan CJD surveillance, South Korea CWD testing).

Companies that successfully combine RT-QuIC expertise, immunoassay portfolio, and regulatory compliance (FDA, EMA, PMDA, OIE) will capture share in a $2.5 billion market by 2032.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp